In support of our finding, mechanisms other than MYC/MYCN downregulation contribute to BETi activity, because inhibition of cell proliferation has been reported even with no reduction, or even an increase, of these transcription factors in lines from different tumor types [23,27,41]. The gene discussed is MYCN; the disease is neoplasm.